IDEAYA Biosciences appoints Dr. Theodora Ross as Chief Development Officer

IDEAYA Biosciences Inc. (NASDAQ: IDYA) announced the appointment of Dr. Theodora Ross as Chief Development Officer, a newly created position at the precision medicine oncology company.

Dr. Ross will lead early clinical development for IDEAYA's oncology pipeline and contribute to the company's long-term research and development strategy, according to a company statement. She joins IDEAYA from AbbVie, where she served as Vice President, Head of Early Oncology R&D and Site Head for the Bay Area.

The appointment brings more than 30 years of oncology experience to IDEAYA. During her tenure at AbbVie, Dr. Ross led the advancement of five early clinical stage programs from first-in-human to Phase 1/2 clinical proof-of-concept studies across various solid tumor indications. She also served as the R&D champion for AbbVie's $10 billion acquisition of Immunogen for the company's oncology asset Elahere.

Dr. Ross previously held positions at Amgen as Vice President of Global Development, Head of Precision Medicine, and Thoracic Oncology, and served as Vice President of Translational Medicine at Merck. Earlier in her career, she headed the Cancer Genetics Department at University of Texas Southwestern Medical Center and maintained a 20-year tenure as an oncologist, laboratory scientist and professor at cancer centers and academic institutions including UTSW and the University of Michigan.

She received her medical degree and Ph.D. from Washington University and completed her residency in internal medicine at Brigham and Women's Hospital, Harvard Medical School, followed by an oncology fellowship at Dana-Farber Cancer Institute, Harvard Medical School.

You May Also Be Interested In